PRECIGEN, INC. Deferred Income Tax Liabilities, Net
PRECIGEN, INC. (PGEN) had Deferred Income Tax Liabilities, Net of $0 as of 2024-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2025-03-19
- 2024-12-31: Deferred Income Tax Liabilities, Net $0.00.
- 2024-09-30: Deferred Income Tax Liabilities, Net $89.00K.
- 2024-06-30: Deferred Income Tax Liabilities, Net $77.00K.
- 2024-03-31: Deferred Income Tax Liabilities, Net $1.78M.
| Period end | Deferred Income Tax Liabilities, Net | Deferred Income Tax Liabilities, Net as first filed |
|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-19 | |
| 2024-09-30 | $89.00K 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $77.00K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $1.78M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $1.85M 10-K · filed 2025-03-19 | |
| 2023-09-30 | $2.13M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $2.18M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $2.24M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $2.26M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $2.09M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $2.26M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $2.44M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $2.54M 10-K · filed 2023-03-06 | |
| 2021-09-30 | $2.57M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $2.69M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $2.72M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $2.90M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $2.73M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $2.70M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $2.79M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $2.83M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $5.73M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $6.33M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $6.72M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $3.86M 10-K · filed 2020-03-02 | $7.21M 10-K · filed 2019-03-01 |
| 2017-12-31 | $15.62M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |